Biogen shares plunge after Alzheimer’s drug setback

Biotech giant halts late-stage trials as results disappoint

22nd March, 2019
Biogen shares plunge after Alzheimer’s drug setback
Pic: Getty

Shares in Biogen plummeted yesterday after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback to efforts to find a therapy for the neurodegenerative ailment.

Shares dropped by as much as 29 per cent in heavy trading, knocking about $18 billion off the company’s market value and marking its biggest intraday stock drop since 2008.

The US-based company said...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Benefits of climate change ‘far outweighed’ by damage, says Varadkar

Club king Fox wonders where Dublin nightlife is going

Fianna Fáil support plunges after ‘Votegate’

Budget 2020: Donohoe adopts an election footing